
News|Articles|July 9, 2007
Latebreakers: Once daily PAH drug OK'd
Ambrisentan (Letairis) in 5-and 10-mg tablets has been approved by the FDA for the treatment of pulmonary arterial hypertension (PAH).
Advertisement
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Pharmacists Provide Tailored Pneumococcal Vaccines to Patients With Down Syndrome
2
Finerenone Shows Benefits for Chronic Kidney Disease for Patients With Type 1 Diabetes
3
FDA Approves Lumateperone as Adjunct Therapy for Major Depressive Disorder
4
Pharmacists’ Expanding Roles in Diabetes, Community Health Care
5




















































































































































